Day: November 12, 2025

– Nearly $250 Million of Recent Capital Raises at GEG and its Credit and Real Estate Vehicles Position Company to Drive Continued Growth – – Pro Forma Fee-Paying AUM and AUM Grew 10% and 7% Year-Over-Year, Respectively, at September 30, 2025 1,2 –– Monomoy BTS Sells Second Build-to-Suit Development Property for $7.4 Million – Company to Host Conference Call at 8:30 a.m. ET on November 13, 2025 PALM BEACH GARDENS, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) — Great Elm Group, Inc. (“we,” “our,” “GEG,” “Great Elm,” or “the Company”), (NASDAQ: GEG), an alternative asset manager, today announced financial results for its fiscal first quarter ended September 30, 2025.  Management Commentary Jason Reese, Chief Executive Officer of the Company stated, “We are pleased with the continued momentum of our expanding alternative asset management platform,...

Q3 Revenue of $29.0 Million;Net Income of $0.5 Million, an Improvement of $34.2 Million;Adjusted EBITDA of $4.1 Million, an Improvement of $4.7 Million;Extends Maturity of Senior Debt to 2028 LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) — Playboy, Inc. (NASDAQ: PLBY) (the “Company” or “Playboy”), one of the most recognizable and iconic lifestyle brands in the world, today announced financial and operational results for its third fiscal quarter ended September 30, 2025. Comments from Ben Kohn, Chief Executive Officer and President of Playboy “The third quarter marks our third consecutive quarter of growing adjusted EBITDA and further demonstrates the potential of our high-margin, asset-light model. It’s important to note that Q3 adjusted EBITDA was burdened by $2.5 million of litigation costs, and would’ve been $6.6 million without...

All dollar amounts are in USD unless otherwise indicated and abbreviation “M” means million. VANCOUVER, British Columbia, Nov. 12, 2025 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE | ASX: ORE | OTCQX: ORZCF) (“Orezone” or “Company”) is pleased to report its operational and financial results for the three and nine months ended September 30, 2025. The Company will host a conference call and webcast today at 2:00pm PT / 5:00pm ET (November 13, 9:00am AEDT) to discuss the results. Details to join the conference call and webcast are provided at the end of this release. Third Quarter 2025 HighlightsGold production of 23,371 ounces at an AISC of $1,958 per ounce sold Revenue of $68.9M from the sale of 20,350 ounces at an average realized price of $3,375 per ounce Adjusted EBITDA of $28.4M, Adjusted Earnings attributable to...

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — Flutter Entertainment plc (NYSE: FLUT; LSE: FLTR) (“Flutter”) the world’s leading online sports betting and iGaming operator today announces Q3 results, updated 2025 guidance, and the launch of “FanDuel Predicts” in December.  Key financial highlights:  Three months ended September 30,In $ millions except where stated otherwise 2025 2024 YOY       Average monthly players (AMPs) (‘000s’)1 14,133 12,920 +9%Revenue 3,794 3,248 +17%Net loss (789) (114) (592)%Net loss margin (20.8)% (3.5)% (1,730)bpsAdjusted EBITDA2 478 450 +6%Adjusted EBITDA margin2 12.6% 13.9% (130)bpsLoss per share ($) (3.91) (0.58) (574)%Adjusted earnings per share ($)2 1.64 1.27 +29%Net cash provided by operating activities 209 290 (28)%Free Cash Flow2 25 112 (78)%Leverage...

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three key readouts: ORKA-001 Phase 2a and 2b (EVERLAST-A and -B), and ORKA-002 Phase 2 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 ORKA-001 Phase 2a trial enrolling well with data expected 2H 2026 MENLO PARK, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported third quarter 2025 financial results and provided a corporate update. “We had a very successful quarter where we released our...

DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) — authID® (Nasdaq: AUID) (“authID” or the “Company”), a leading provider of biometric identity verification and authentication solutions, today reported financial and operating results for the third quarter ended September 30, 2025. Third Quarter 2025 vs. Third Quarter 2024 Financial SummaryGross revenue for the quarter was $0.6 million, compared to $0.2 million a year ago. Net revenue for the quarter, after accounting for one-time concessions, was negative $(0.1) million, compared with $0.2 million a year ago Operating expenses were $5.1 million, compared to $3.8 million a year ago. Net loss was $5.2 million, or $0.38 per share, compared to a loss of $3.4 million, or $0.31 per share a year ago. Adjusted EBITDA Loss of $4.1 million (non-GAAP measure as defined below), compared with $2.9...

Completed strategic pivot from R&D focus to commercial focus Rebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relations Advanced multiple recombinant protein programs toward commercialization Achieved key development and commercial milestones across life sciences and nutrition markets First purchase order received in cell culture media and molecular biology reagent segments Secured ERS Genomics CRISPR license to optimize production and product performance Strengthened liquidity and cash position through the completion of equity offering Cash, cash equivalents, restricted cash and cash equivalent, and investment grade securities of $10.4 million as of September 30, 2025 Dyadic to host an earnings call at 5:00 pm ETJUPITER, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE)...

– Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP – – Raised $225 million of financing, including $25 million private placement with Sanofi – – Cash runway extended into 2029, including through topline readout of planned Phase 3 trial of atebimetinib + mGnP in first-line pancreatic cancer – – Granted U.S. composition of matter patent for atebimetinib that is expected to provide exclusivity into 2042 – – New reports of first-line pancreatic cancer patients with excellent responses to atebimetinib + FOLFIRINOX, including a patient with a complete response and a responding patient who was able to advance to radiation and surgery with curative intent – – Conference call scheduled for today, November...

Company Updates FY 2025 Revenue Guidance from $111.0 Million to $113.0 Million to approximately $104.0 Million FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — SoundThinking, Inc. (Nasdaq: SSTI), a leading public safety technology company, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial and Operational HighlightsRevenues decreased 4% to $25.1 million, compared to $26.3 million for the same quarter of 2024. Gross profit decreased 10% to $13.6 million (54% of revenues), compared to $15.2 million (58% of revenues) for the same quarter of 2024. GAAP net loss totaled $2.0 million, compared to GAAP net loss of $1.4 million for the same quarter of 2024. Adjusted EBITDA1 totaled $3.5 million (14% of revenues), compared to $4.5 million (17% of revenues) for the same quarter...

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 Tenax to Host Virtual KOL Call Tomorrow, Thursday, November 13, 2025 at 4:30 p.m. ET CHAPEL HILL, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial results for the quarter ended September 30, 2025 and provided an update on its recent corporate progress. “We continued to advance our lead program, TNX-103, in patients with PH-HFpEF and remain on track to enroll 230 patients in the ongoing Phase 3 LEVEL...